Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with hematologic malignancies. However, there are no recommendations to guide diagnosis and management. The European Conference on Infections in Leukemia assigned experts in hematology and infectious diseases to develop evidence-based recommendations for the diagnosis and treatment of mucormycosis. The guidelines were developed using the evidence criteria set forth by the American Infectious Diseases Society and the key recommendations are summarized here. In the absence of validated biomarkers, the diagnosis of mucormycosis relies on histology and/or detection of the organism by culture from involved sites with identification of the isolate at the species level (no grading). Antifungal chemotherapy, control of the underlying predisposing condition, and surgery are the cornerstones of management (level A II). Options for first-line chemotherapy of mucormycosis include liposomal amphotericin B and amphotericin B lipid complex (level B II). Posaconazole and combination therapy of liposomal amphotericin B or amphotericin B lipid complex with caspofungin are the options for second line-treatment (level B II). Surgery is recommended for rhinocerebral and skin and soft tissue disease (level A II). Reversal of underlying risk factors (diabetes control, reversal of neutropenia, discontinuation/taper of glucocorticosteroids, reduction of immunosuppressants, discontinuation of deferroxamine) is important in the treatment of mucormycosis (level A II). The duration of antifungal chemotherapy is not defined but guided by the resolution of all associated symptoms and findings (no grading). Maintenance therapy/secondary prophylaxis must be considered in persistently immunocompromised patients (no grading).

[1]  R. Porcher,et al.  Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  T. Walsh,et al.  Rhino-Orbital-Cerebral Mucormycosis , 2012, Current Infectious Disease Reports.

[3]  B. Spellberg,et al.  Combination therapy for mucormycosis: why, what, and how? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. Kwon-Chung Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Marlis Täger F,et al.  [Cutaneous mucormycosis in an immunocompromised patient]. , 2012, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[7]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  J. Perfect,et al.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. , 2011, The Journal of antimicrobial chemotherapy.

[9]  J. Wingard,et al.  Assessing Responses to Treatment of Opportunistic Mycoses and Salvage Strategies , 2011, Current infectious disease reports.

[10]  H. Dombret,et al.  Breakthrough zygomycosis following empirical caspofungin treatment: report of two patients with leukemia and literature review , 2010 .

[11]  K. Gupta,et al.  Rhino-Orbital-Cerebral Zygomycosis in Solid Organ Transplant Recipients , 2010, Transplantation.

[12]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Rodríguez-Tudela,et al.  Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation , 2010, Journal of Clinical Microbiology.

[14]  S. Magill,et al.  Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. , 2010, Medical mycology.

[15]  D. Kontoyiannis,et al.  Comparative Pharmacodynamics of Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Murine Model of Pulmonary Mucormycosis , 2009, Antimicrobial Agents and Chemotherapy.

[16]  G. Bug,et al.  Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  A. Simon,et al.  Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.

[18]  V. Sakhuja,et al.  Invasive zygomycosis in India: experience in a tertiary care hospital , 2009, Postgraduate Medical Journal.

[19]  K. Gupta,et al.  Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. , 2009, The Journal of infectious diseases.

[20]  J. Desenclos,et al.  Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006 , 2009, Emerging infectious diseases.

[21]  K. Gupta,et al.  Pulmonary Zygomycosis in Solid Organ Transplant Recipients in the Current Era , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  E. Dannaoui,et al.  An increasing trend of cutaneous zygomycosis caused by Mycocladus corymbifer (formerly Absidia corymbifera): report of two cases and review of primary cutaneous Mycocladus infections. , 2009, Medical mycology.

[23]  D. Howard,et al.  Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  Li Li,et al.  Primary Cutaneous Mucormycosis Caused by Rhizomucor variabilis in an Immunocompetent Patient , 2009, Mycopathologia.

[25]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  C. Romano,et al.  Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) , 2009, Journal of chemotherapy.

[27]  M. Ghannoum,et al.  In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries , 2009, Journal of chemotherapy.

[28]  B. Spellberg,et al.  Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis , 2009, Antimicrobial Agents and Chemotherapy.

[29]  G. Alangaden,et al.  A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro. , 2009, Diagnostic microbiology and infectious disease.

[30]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  C. Lass‐Flörl,et al.  In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2009, Antimicrobial Agents and Chemotherapy.

[32]  B. Spellberg,et al.  Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment , 2008, Current opinion in infectious diseases.

[33]  B. Spellberg,et al.  Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[34]  K. Marr,et al.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  G. Socié,et al.  Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[36]  G. Hasçelik,et al.  Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. , 2008, Medical mycology.

[37]  J. Perfect,et al.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Kontoyiannis,et al.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Guarro,et al.  Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae , 2008, Antimicrobial Agents and Chemotherapy.

[40]  R. Goldberg,et al.  Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  M. Dierich,et al.  Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[42]  C. Gil-Lamaignere,et al.  Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes , 2008, Mycoses.

[43]  J. Greenwood,et al.  Primary Cutaneous Zygomycosis in a Burns Patient: A Review , 2008, Journal of burn care & research : official publication of the American Burn Association.

[44]  D. Stevens,et al.  Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[45]  J. Mira,et al.  Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[46]  B. Spellberg,et al.  Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.

[47]  G. Gastl,et al.  The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  B. Spellberg,et al.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation. , 2007, The Journal of clinical investigation.

[49]  L. Gordon,et al.  Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.

[50]  T. Walsh,et al.  Zygomycosis in Children: A Systematic Review and Analysis of Reported Cases , 2007, The Pediatric infectious disease journal.

[51]  S. Gupta,et al.  Rhinocerebral mucormycosis: the disease spectrum in 27 patients , 2007, Mycoses.

[52]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  R. Ebrahimi,et al.  Liposomal amphotericin B (AmBisome®) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis , 2007, Mycoses.

[54]  M. Rinaldi,et al.  In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[55]  V. Rickerts,et al.  Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  T. Peláez,et al.  In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest , 2006, Antimicrobial Agents and Chemotherapy.

[57]  L. Gordon,et al.  Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole. , 2006 .

[58]  D. Kontoyiannis,et al.  Erratum: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases (Clinical Infectious Diseases (April 1, 2006) 42 (e61-e65)) , 2006 .

[59]  A. Santinelli,et al.  Posaconazole Prophylaxis in Experimental Systemic Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[60]  M. Ghannoum,et al.  Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi , 2006, Journal of Clinical Microbiology.

[61]  J. Fung,et al.  Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the Literature , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[62]  B. Spellberg,et al.  Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis , 2006, Antimicrobial Agents and Chemotherapy.

[63]  A. Shin,et al.  Upper-extremity mucormycosis infections in immunocompetent patients. , 2006, The Journal of hand surgery.

[64]  V. Sakhuja,et al.  The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. , 2006, Medical mycology.

[65]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  T. Walsh,et al.  Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay , 2006, Journal of Clinical Microbiology.

[67]  M. Schuster,et al.  Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[68]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  T. Walsh,et al.  Posaconazole: clinical pharmacology and potential for management of fungal infections , 2005, Expert review of anti-infective therapy.

[70]  D. Kontoyiannis,et al.  Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  D. Kontoyiannis,et al.  Hyperbaric oxygen as an adjunctive treatment for zygomycosis. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[72]  R. Kappe,et al.  In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38‐A microdilution method , 2005, Mycoses.

[73]  F. Müller,et al.  Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. , 2005, The Journal of antimicrobial chemotherapy.

[74]  T. Walsh,et al.  Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. , 2005, The Journal of infectious diseases.

[75]  H. Hayashi,et al.  Cutaneous Mucormycosis in a Patient with Acute Lymphocytic Leukemia , 2005, The Journal of dermatology.

[76]  B. Spellberg,et al.  Caspofungin Inhibits Rhizopus oryzae 1,3-β-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis , 2005, Antimicrobial Agents and Chemotherapy.

[77]  B. Spellberg,et al.  Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.

[78]  J. Brutus,et al.  Atypical Cause of Forearm Skin Ulceration in a Leukaemic Child: Mucormycosis. A Case Report , 2005, Acta chirurgica Belgica.

[79]  D. Stevens,et al.  Paradoxical Effect of Caspofungin: Reduced Activity against Candida albicans at High Drug Concentrations , 2004, Antimicrobial Agents and Chemotherapy.

[80]  E. Thiel,et al.  Improved Outcome of Zygomycosis in Patients with Hematological Diseases? , 2004, Leukemia & lymphoma.

[81]  J. Robson,et al.  Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis , 2004, Mycoses.

[82]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[83]  Lisardo García-Covarrubias,et al.  Tratamiento adjunto con oxigenación hiperbárica en mucormicosis. Presentación de cinco casos tratados en la misma Institución y revisión de la literatura , 2004 .

[84]  J. Meis,et al.  Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis , 2003, Antimicrobial Agents and Chemotherapy.

[85]  M. Okudaira,et al.  Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: Comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997 , 2003, Pathology international.

[86]  B. Spellberg,et al.  Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae , 2003, Antimicrobial Agents and Chemotherapy.

[87]  S. Pereyre,et al.  DNA Gyrase and Topoisomerase IV Mutations in Clinical Isolates of Ureaplasma spp. and Mycoplasma hominis Resistant to Fluoroquinolones , 2003, Antimicrobial Agents and Chemotherapy.

[88]  Reji Thomas,et al.  Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. , 2003, Indian journal of ophthalmology.

[89]  S. Chanock,et al.  Immunomodulation of invasive fungal infections. , 2003, Infectious disease clinics of North America.

[90]  D. Loebenberg,et al.  In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model , 2002, Antimicrobial Agents and Chemotherapy.

[91]  J. Meis,et al.  Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis , 2002, Antimicrobial Agents and Chemotherapy.

[92]  J. Graybill,et al.  In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes , 2002, Antimicrobial Agents and Chemotherapy.

[93]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  E. Anaissie,et al.  Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study , 2001, Antimicrobial Agents and Chemotherapy.

[95]  E. Anaissie,et al.  Treatment of 21 Cases of Invasive Mucormycosis with Amphotericin B Colloidal Dispersion , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[96]  G. Pankey,et al.  Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  W. Peitsch,et al.  Cryptococcosis in patients with cancer. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[98]  S. Piscitelli,et al.  Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. , 2000, The Journal of infectious diseases.

[99]  D. Kontoyiannis,et al.  Zygomycosis in the 1990s in a tertiary-care cancer center. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  S. Mossad,et al.  Pulmonary mucormycosis: the last 30 years. , 1999, Archives of internal medicine.

[101]  W. Liles,et al.  Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. , 1999, The Journal of infectious diseases.

[102]  A. Espinel-Ingroff Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts , 1998, Journal of Clinical Microbiology.

[103]  E. Brummer,et al.  Activity of Voriconazole Combined with Neutrophils or Monocytes against Aspergillus fumigatus: Effects of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1998, Antimicrobial Agents and Chemotherapy.

[104]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  J. Hollender,et al.  Luftverbreitete Schimmelpilze und deren Stoffwechselmetabolite an Arbeitsplätzen in Kompostieranlagen , 1998 .

[106]  A. Al-Shami,et al.  Granulocyte-Macrophage Colony-stimulating Factor-activated Signaling Pathways in Human Neutrophils , 1998, The Journal of Biological Chemistry.

[107]  W. Liles,et al.  Effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) on neutrophil kinetics and function in normal human volunteers , 1998, American journal of hematology.

[108]  L. Pagano,et al.  Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases , 1997, British journal of haematology.

[109]  W. Liles,et al.  Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. , 1997, The Journal of infectious diseases.

[110]  T. Ekfors,et al.  THE USE OF IMMUNOHISTOCHEMISTRY TO IMPROVE SENSITIVITY AND SPECIFICITY IN THE DIAGNOSIS OF SYSTEMIC MYCOSES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES , 1997, The Journal of pathology.

[111]  A. Silvestrini,et al.  Effect in vitro of gamma interferon and interleukin-10 on generation of oxidizing species by human granulocytes , 1996, Inflammation Research.

[112]  B. Oppenheim,et al.  The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[113]  Z. Yao,et al.  Pyoderma gangraenosum caused by Rhizopus arrhizus , 1995, Mycoses.

[114]  R. Markert,et al.  Survival factors in rhino-orbital-cerebral mucormycosis. , 1994, Survey of ophthalmology.

[115]  J. Lowe,et al.  Pulmonary mucormycosis: results of medical and surgical therapy. , 1994, The Annals of thoracic surgery.

[116]  A. Kapp,et al.  Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. , 1990, The Journal of investigative dermatology.

[117]  T. G. Mitchell,et al.  Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. , 1988, Reviews of infectious diseases.

[118]  C. Lass‐Flörl Zygomycosis: conventional laboratory diagnosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[119]  A. Groll,et al.  Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[120]  E. Dannaoui,et al.  Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[121]  S. Jalal,et al.  Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[122]  S Zaher,et al.  Clinical Infectious Disease: Clinical Syndromes – Respiratory Tract , 2008 .

[123]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[124]  L. Pagano,et al.  Design and Methods , 2022 .

[125]  D. Subirá,et al.  Aspergillus fumigatus: a rare cause of vertebral osteomyelitis. , 2004, Haematologica.

[126]  K. V. Van Meter,et al.  [Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated at the same institution and review of the literature]. , 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[127]  L. Pagano,et al.  Mucormycosis in hematologic patients. , 2004, Haematologica.

[128]  J. Montero,et al.  Efficacy and safety of amphotericin B lipid complex for zygomycosis , 2003 .

[129]  J. Meis,et al.  In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.

[130]  G. Carrafiello,et al.  Mucormycosis in hematologic malignancies: an emerging fungal infection. , 2000, Haematologica.